EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
89.57
-2.61 (-2.83%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close92.18
Open92.42
Bid89.45 x 900
Ask89.66 x 1400
Day's Range87.74 - 92.71
52 Week Range75.35 - 123.99
Volume1,745,470
Avg. Volume2,389,354
Market Cap13.188B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb. 18, 2020 - Feb. 23, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est124.21
  • Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day
    Zacks

    Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day

    Exact Sciences, GameStop, Intel, Intuitive Surgical and Skyworks highlighted as Zacks Bull and Bear of the Day

  • What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
    Zacks

    What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?

    IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.

  • Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?
    Zacks

    Can Critical Care Aid Edwards Lifesciences (EW) Q4 Earnings?

    Robust customer adoption of the HemoSphere all-in-one monitoring platform is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.

  • Bull of the Day: Exact Sciences (EXAS)
    Zacks

    Bull of the Day: Exact Sciences (EXAS)

    Bull of the Day: Exact Sciences (EXAS)

  • Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?
    Zacks

    Will New Buyouts Aid Quest Diagnostics (DGX) Q4 Earnings?

    Quest Diagnostics' (DGX) acquisition of Clinical Laboratory Services of Boston Clinical Laboratories is expected to have been accretive to its Q4 earnings.

  • Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?
    Zacks

    Will Segmental Growth Aid Hologic (HOLX) in Q1 Earnings?

    Strength in segmental businesses is likely to have aided Hologic's (HOLX) performance in first-quarter fiscal 2020.

  • What's in Store for Align Technology's (ALGN) Q4 Earnings?
    Zacks

    What's in Store for Align Technology's (ALGN) Q4 Earnings?

    Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.

  • Is Exact Sciences Corporation (NASDAQ:EXAS) Trading At A 40% Discount?
    Simply Wall St.

    Is Exact Sciences Corporation (NASDAQ:EXAS) Trading At A 40% Discount?

    How far off is Exact Sciences Corporation (NASDAQ:EXAS) from its intrinsic value? Using the most recent financial...

  • Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
    Zacks

    Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

    Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

  • Zacks

    Another Milestone After Another Trade Deal

    Another Milestone After Another Trade Deal

  • Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls
    Zacks

    Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls

    Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.

  • Novavax Rises on Fast Track Designation to Influenza Vaccine
    Zacks

    Novavax Rises on Fast Track Designation to Influenza Vaccine

    The FDA bestows a Fast Track Designation on Novavax's (NVAX) influenza vaccine candidate NanoFlu for adults aged 65 years and older. Shares rally.

  • Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results
    Zacks

    Perrigo (PRGO) Rises on Stellar Q419 Preliminary Results

    Perrigo (PRGO) announces better-than-expected preliminary results for fourth-quarter 2019 as well as the full year. Shares gain.

  • Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
    Zacks

    Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?

    OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.

  • Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Exact Sciences (EXAS) Outpaced Other Medical Stocks This Year?

    Is (EXAS) Outperforming Other Medical Stocks This Year?

  • Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
    Zacks

    Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?

    Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.

  • Top Ranked Momentum Stocks to Buy for January 13th
    Zacks

    Top Ranked Momentum Stocks to Buy for January 13th

    Top Ranked Momentum Stocks to Buy for January 13th

  • Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
    Zacks

    Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?

    Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.

  • Exact Sciences Rides on Cologuard, Eyes Merger Synergies
    Zacks

    Exact Sciences Rides on Cologuard, Eyes Merger Synergies

    Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

  • Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?
    Zacks

    Walgreens Boots (WBA) to Post Q1 Earnings: What's in Store?

    Higher comparable pharmacy sales and expanded comparable prescription volume are likely to have aided growth in Walgreens Boots' (WBA) Retail Pharmacy USA during the first quarter of fiscal 2020.

  • Bitcoin’s 9,000,000% Rise This Decade Leaves the Skeptics Aghast
    Bloomberg

    Bitcoin’s 9,000,000% Rise This Decade Leaves the Skeptics Aghast

    (Bloomberg) -- If in the throes of this bull market’s earliest stages of recovery someone told you to forgo stocks, forget commodities, renounce fixed-income assets and buy an unknown digital token, the first of its kind, and watch it grow beyond your wildest dreams, you’d call them crazy, right?Emerging out of the ashes of the financial crisis, Bitcoin was created as a bypass to the banks and government agencies mired in Wall Street’s greatest calamity in decades. At first, it was slow to break through, muddied by a slew of scandals: fraud, thefts and scams that turned away many and brought closer regulatory scrutiny. But once it burst into the mainstream, it proved to be the decade’s best-performing asset.The largest digital token, trading around $7,200, has posted gains of more than 9,000,000% since July 2010, according to data compiled by Bloomberg.“Bitcoin really captured that wild technology enthusiasm that ‘this time is different,’” said Peter Atwater, the president of Financial Insyghts and an adjunct professor at William & Mary in Williamsburg, Virginia.The performance over the past 10 years, even with its huge run-up and subsequent mega-crash, leaves all others in the dust. It’s a massive windfall for those who HODL’ed through its ups and downs, even as it continues to provide fodder for get-rich-quick schemes. For some, the never-ending fantasy of continually hitting that payoff still helps to keep Bitcoin’s momentum going.Nothing else comes even close to beating it. The S&P 500 merely tripled in that period. An index that tracks world markets has more than doubled. Gold is up 25%. Some of the best-performing stocks in the Russell 3000 -- including Exact Sciences Corp. and Intelligent Systems Corp. -- are each up about 3,000%. Those gains pale in comparison to the finance world’s latest -- and one of its most controversial -- marvels.Partly, the monster return is a reflection of the calculus behind Bitcoin’s jumping-off point: the token wasn’t worth anything when someone named Satoshi Nakamoto launched it on Halloween 2008. Designed as a method of exchange that can be sent electronically between users around the world, it did not have a centralized control network. Bitcoin, instead, is run by a network of computers that keep track of all transactions on the blockchain ledger. For many, that technology was reason enough to buy into the idea.On the other side of the equation are Bitcoin’s devoted enthusiasts who saw in its technology a promising way to change the global financial system.“This is the first time that there’s a real separation -- just like church and state -- you have a separation of money and state,” said Alex Mashinsky, founder of Celsius Network, a crypto lending platform. “That’s the innovation, that’s the excitement.”But Bitcoin was slow to take off, notching its first transaction two years after its creation, when someone used it to buy pizza. Since then, the first-born token’s price has catapulted, doubling many times over, and hundreds of imitators have cropped up -- some with more success than others.Many of those who got in early stayed faithful, watching as it made its way through a boom and bust cycle unrivaled by almost anything else over the last decade.At the beginning of 2017, Bitcoin jumped above $1,000. By mid-summer, it had more than doubled. Insanity was unleashed. By year-end, it hovered above $14,000. But as swiftly as it ran up, it fell even faster. By the end of 2018, Bitcoin barely budged above $3,000. Yet shortly after its crash, it embarked on another huge rally, this time reaching as high as $13,800 in the summer of 2019.“Certainly the numbers are what appeals to investors,” said David Tawil, president of ProChain Capital. “The next 10 years need to be a totally different stage of growth based on totally different factors than the first stage.”As much as it’s made a fortune for speculators and some thieves, Bitcoin’s survival will rest on further adoption. It’s not being used as a widespread medium of exchange. A few large retailers are accepting payment in Bitcoin but it hasn’t been the large-scale embrace so many had predicted. Scams are still running rampant. Interest is waning and consolidation among large owners is at a higher level than it was during the height of the 2017 bubble, which means that their influence over prices could be increasing.Projections for the next decade abound. In the 2020s, mass adoption is surely to take off, they say. Blockchain technology will revolutionize and solve every problem in the world. On the other hand, regulatory scrutiny is likely to intensify, with central bankers paying closer attention than ever before.In the more immediate term, some speculators forecast 2020 might be less fraught with volatility given its upcoming halving, whereby the number of coins awarded to so-called miners who process transactions is cut by 50%. That’s set to happen in May 2020 (the internet is replete with countdown clocks). The coin’s previous cut, about four years ago, coincided with a run-up in its price, pushing many crypto evangelist to believe in a repeat.To CoinList’s Andy Bromberg, the halving is already priced in. “Maybe it’s been overpriced in and everyone’s bought into this thesis and we see a dip post-halving,” said the firm’s co-founder and president in an interview. “That would not shock me.”But beyond next year, “Bitcoin is finding its own narrative as digital gold,” he said. “It feels like that narrative is picking up steam and it’s breaking away on its own. I would define success for most crypto assets as doing exactly that.”To contact the reporter on this story: Vildana Hajric in New York at vhajric1@bloomberg.netTo contact the editors responsible for this story: Jeremy Herron at jherron8@bloomberg.net, Dave Liedtka, Randall JensenFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.

  • Exact Sciences Corporation's (NASDAQ:EXAS) Path To Profitability
    Simply Wall St.

    Exact Sciences Corporation's (NASDAQ:EXAS) Path To Profitability

    Exact Sciences Corporation's (NASDAQ:EXAS): Exact Sciences Corporation, a molecular diagnostics company, focuses on...

  • Medtronic (MDT) to Report Q2 Earnings: What's in Store?
    Zacks

    Medtronic (MDT) to Report Q2 Earnings: What's in Store?

    In the fiscal second quarter, Medtronic (MDT) is expected to have registered strong growth in its ICD and CRT product lines.

  • If You Had Bought Exact Sciences (NASDAQ:EXAS) Shares Three Years Ago You'd Have Made 373%
    Simply Wall St.

    If You Had Bought Exact Sciences (NASDAQ:EXAS) Shares Three Years Ago You'd Have Made 373%

    Exact Sciences Corporation (NASDAQ:EXAS) shareholders might be concerned after seeing the share price drop 29% in the...